Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

TOMI Environmental Solutions, Inc. Starts New Year With Inclusion in EPA Lists G, L, and M

Posted on: 27 Dec 17

BEVERLY HILLS, Calif., Dec. 27, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination company that specializes in disinfection/decontamination sales and services, including SteraMist™, a hydrogen peroxide-based mist/fog registered with the U.S. Environmental Protection Agency (“EPA”) for use as a hospital-healthcare disinfectant, is set to be included in the EPA’s Lists G, L, and M. This inclusion validates that the EPA recognizes that SteraMist™ products meet or exceed efficacy requirements for some of the most life threatening pathogens that challenge public health around the globe today. Publication of these additions will follow shortly.

Inclusion to List G demonstrates efficacy against Norovirus, a virus that has recently prompted many public health officials nationwide to increase community awareness of the symptoms of and ways to combat the spread of this highly contagious disease. In July 2017, the EPA approved and expanded the current label to include Norovirus and Salmonella.

List L is a listing of approved disinfectants for use against the Ebola Virus. This list of registered disinfectants meets the Center for Disease Control’s (CDC) criteria for use against the Ebola virus on hard, non-porous surfaces.  List M provides a list of registered antimicrobial products with label claims for Avian (Bird) Flu Disinfectants. These EPA disinfectant products are registered and labeled with a claim to inactivate Avian influenza A viruses on hard, non-porous surfaces. Although there are no antimicrobial products registered specifically against the H5N2 subtype of Avian Influenza A virus the EPA believes, based on available scientific information, that registered Avian Influenza A products will be effective against the H5N2 strain and other strains.

Dr. Halden Shane, TOMI CEO, has stated, “This is a fantastic way for TOMI to wrap up the year on the regulatory front with three new sought after EPA inclusions on lists G, L, and M, a perfect trifecta. Our SteraMist™ plasma technology is now on all four of the EPA’s antimicrobial lists,  including the much in demand K list for killing C. difficule spores. TOMI enters 2018 ready to show the world that SteraMist™ can surpass all competitors in the decontamination space in relation to speed, efficacy, material compatibility and cost effectiveness.”

About TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BIT™ uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (OH ion), represented by the TOMI™ SteraMist™ brand of products, which produces a germ-killing aerosol that works like a visual non-caustic gas.

TOMI’s products are designed to service a broad spectrum of commercial structures including but not limited to hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities (when not in operation), military barracks, police and fire departments, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.

TOMI also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association.

For additional information, please visit or contact us at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.

Juliana deRosa
Executive Administrator


Last updated on: 29/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.